
#128 – IDWeek 2025 Recap
Breakpoints
00:00
REVIST: S‑Trimani Avibactam versus Meropenem
Julie reviews REVISIT trial comparing s-trianam‑avibactam to meropenem for IAI and HAP/VAP; enrollment limited for MBL isolates.
Play episode from 55:58
Transcript


